QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-downgrades-replimune-group-to-underweight

JP Morgan analyst Anupam Rama downgrades Replimune Group (NASDAQ:REPL) from Neutral to Underweight.

 replimune-group-completes-type-a-meeting-with-fda-on-rp1-bla-for-advanced-melanoma-path-forward-for-accelerated-approval-still-undetermined

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immun...

 hc-wainwright--co-reiterates-neutral-on-replimune-groupto-neutral

HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) from Neutral to Neutral.

 replimune-group-q1-eps-095-misses-084-estimate

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0...

 why-is-replimune-stock-trading-lower-on-monday

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION